Global /United States /Healthcare /Drug Manufacturers - General /SVRA

Savara Inc.

SVRA

• NASDAQ: SVRA • Delayed

4.85USD -3.4%

As of 13 June 2026, Savara Inc. has a market cap of $1.23B USD, ranking #9535 globally and #2032 in the United States. It ranks #823 in the Healthcare sector, and #311 in the Drug Manufacturers - General industry.

Global Rank

9535

Country Rank

2032

Sector Rank

823

Industry Rank

311

Key Stats

Market Cap

$1.23BUSD

Enterprise Value

$1.03BUSD

EBITDA (TTM)

-$122.68MUSD

Net Income (TTM)

-$118.84MUSD

PB Ratio

6.1

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Matthew Pauls open_in_new

Employees

Founded

2007

Website

savarapharma.com open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.4%	-5.6%	-5.6%	-14%	10%	-20%	52%	158%	139%

News

SVRA Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	SVRA Savara Inc ISIN: US8051111016 Shares Out.: Shares Outstanding: 204.927M¹ Shares Float: 106.646M² TV: TradingView: NASDAQ: SVRA SA: Stock Analysis: NASDAQ: SVRA YF: Yahoo Finance: SVRA GF: Google Finance: NASDAQ: SVRA NQ: NASDAQ: SVRA BA: Barron's: SVRA MS: Morningstar: XNAS: SVRA	4.85 USD	TV: TradingView: NASDAQ: SVRA SA: Stock Analysis: NASDAQ: SVRA YF: Yahoo Finance: SVRA GF: Google Finance: NASDAQ: SVRA NQ: NASDAQ: SVRA BA: Barron's: SVRA MS: Morningstar: XNAS: SVRA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 62K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 44K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 29K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 22K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 12K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 9K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 26K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 23K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 22K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 15K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 9K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 9K%	14.6	United Kingdom

chevron_leftBack